The company announced a major $21 billion deal to acquire Exact Sciences, the maker of the Cologuard at-home colon cancer test. This represents the company's largest acquisition in a decade and will allow it to enter the lucrative cancer testing market. The deal includes a significant 50% premium paid for Exact Sciences shares. This strategic move is seen as a key part of the company's future growth strategy, expanding its diagnostic portfolio into early cancer detection.